Olema Pharmaceuticals/$OLMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Ticker
$OLMA
Sector
Primary listing
Employees
137
Headquarters
Website
OLMA Metrics
BasicAdvanced
$858m
-
-$2.03
2.06
-
Price and volume
Market cap
$858m
Beta
2.06
52-week high
$36.26
52-week low
$3.89
Average daily volume
1.3m
Financial strength
Current ratio
10.881
Quick ratio
10.785
Long term debt to equity
0.624
Total debt to equity
0.823
Profitability
EBITDA (TTM)
-191.33
Management effectiveness
Return on assets (TTM)
-25.50%
Return on equity (TTM)
-42.86%
Valuation
Price to book
1.78
Price to tangible book (TTM)
1.79
Price to free cash flow (TTM)
-6.032
Free cash flow yield (TTM)
-16.58%
Free cash flow per share (TTM)
-1.628
Growth
Earnings per share change (TTM)
4.11%
3-year earnings per share growth (CAGR)
-9.59%
What the Analysts think about OLMA
Analyst ratings (Buy, Hold, Sell) for Olema Pharmaceuticals stock.
OLMA Financial Performance
Revenues and expenses
OLMA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs